Oncosil Medical

Oncosil Medical Days Payable Outstanding

The Days Payable Outstanding (DPO) of Oncosil Medical (OSL.AX) as of Nov 20, 2026 is 148.90. In the previous year, Days Payable Outstanding (DPO) was 310.22 — a change of -52.00% (lower).

Days Payable Outstanding

148.90

YoY

-52.00%

Last updated:

Days Payable Outstanding (DPO) of Oncosil Medical is 2026 148.90 . Days Payable Outstanding (DPO) of Oncosil Medical was 2025 310.22 . It decreases by -52.00% lower compared to the previous year.

The Oncosil Medical Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
3,440.33 AUD
Jan 1, 2020
3,314.38 AUD
Jan 1, 2021
466.00 AUD
Jan 1, 2022
349.45 AUD
Jan 1, 2023
220.59 AUD
Jan 1, 2024
271.56 AUD
Jan 1, 2025
310.22 AUD
Jan 1, 2026
148.90 AUD
The Oncosil Medical Days Payable Outstanding history
YEARDays Payable OutstandingYoY
148.90-52.00%
310.22+14.24%
271.56+23.11%
220.59-36.88%
349.45-25.01%
466.00-85.94%
3,314.38-3.66%
3,440.33-56.11%
7,838.20-30.59%
11,292.25+204.91%
3,703.46-60.16%
9,295.39+108.67%
4,454.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncosil Medical Stock analysis

What does Oncosil Medical do? Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncosil Medical stock

Days Payable Outstanding (DPO) of Oncosil Medical is 148.90 in 2026.

Days Payable Outstanding (DPO) of Oncosil Medical changed from 310.22 to 148.90, representing a -52.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Oncosil Medical since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Oncosil Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Oncosil Medical

All Key Metrics — Oncosil Medical